Correlation between metabolic syndrome and malignant degree of renal cell carcinoma
-
摘要: 目的:分析代谢综合征和肾癌恶性程度的相关性。方法:收集2013年1月~2016年1月期间我院收治的668例肾癌手术治疗患者的一般资料,根据有无代谢综合征分为单纯性肾癌组和肾癌合并代谢综合征组。统计分析两组间肾癌Fuhrman分级的差异。结果:本研究共纳入668例肾细胞癌患者,平均年龄为(62.7±9.0)岁,男性451例,女性217例,病理类型为透明细胞癌588例,非透明细胞癌80例。单纯肾癌组包含552例患者,平均年龄(62.5±9.0)岁,男性375例,女性177例,病理类型为透明细胞癌486例,非透明细胞癌66例。Fuhrman分级Ⅰ、Ⅱ级399例,Fuhrman分级Ⅲ、Ⅳ级153例;肾癌合并代谢综合征组包括116例患者,平均年龄(63.7±8.9)岁, 男性76例,女性40例,病理类型为透明细胞癌102例,非透明细胞癌14例。Fuhrman分级Ⅰ、 Ⅱ级71例,Fuhrman分级Ⅲ、Ⅳ级45例。肾癌合并代谢综合征组患者的Fuhrman分级明显高于单纯肾癌组,且存在统计学意义(P=0.018)。结论:肾癌伴有代谢综合征预示了更高的恶性程度。Abstract: Objective: To analyze the correlation between metabolic syndrome and malignant degree of renal cell carcinoma.Method: The general data of 668 patients with renal cell carcinoma treated in our hospital from January 2013 to January 2016 were collected and divided into two groups according to whether is accompanied by metabolic syndrome. The statistical analysis was made in the different Fuhrman grades between two groups. Result: The study included 668 patients with renal cell carcinoma, with an average age of (62.7±9.0) years old. There were 451 males and 217 females. Pathological type showed clear cell carcinoma in 588 cases, non-clear cell carcinoma in 80 cases. The non-metabolic syndrome group included 552 patients, whose mean age was (62.5±9.0) years old. There were 375 males and 177 females. Pathological type showed clear cell carcinoma in 486 cases and non-clear cell carcinoma in 66 cases. Fuhrman grade Ⅰ, Ⅱ were found in 399 cases and grade Ⅲ, Ⅳ were found in 153 cases. The metabolic syndrome group included 116 patients whose mean age was (63.7±8.9) years old. There were 76 males and 40 females. Pathological type showed clear cell carcinoma in 102 cases and non-clear cell carcinoma in 14 cases. Fuhrman grade Ⅰ, Ⅱ were found in 71 cases and grade Ⅲ, Ⅳ were found in 45 cases. Patients with metabolic syndrome had significantly higher Fuhrman grade with a statistical significance (P=0.018).Conclusion: Renal cell carcinoma associated with metabolic syndrome indicates a higher degree of malignancy.
-
Key words:
- metabolic syndrome /
- renal cell carcinoma /
- Fuhrman grade
-
-
[1] Siegel R L,Miller K D,Jemal A.Cancer statistics,2016[J].CA Cancer J Clin,2016,66(1):7-30.
[2] Chen W,Zheng R,Baade P D,et al.Cancer statistics in China,2015[J].CA Cancer J Clin,2016,66(2):115-132.
[3] Aguilar M,Bhuket T,Torres S,et al.Prevalence of the metabolic syndrome in the United States,2003-2012[J].JAMA,2015,313(19):1973-1974.
[4] Wu Q,Chen G,Wu W M,et al.Metabolic syndrome components and risk factors for pancreatic adenocarcinoma:a case-control study in China[J].Digestion,2012,86(4):294-301.
[5] Lindkvist B,Almquist M,Bjorge T,et al.Prospective cohort study of metabolic risk factors and gastric adenocarcinoma risk in the Metabolic Syndrome and Cancer Project(Me-Can)[J].Cancer Causes Control,2013,24(1):107-116.
[6] Forootan M,Tabatabaeefar M,Yahyaei M,et al.Metabolic syndrome and colorectal cancer:a cross-sectional survey[J].Asian Pac J Cancer Prev,2012,13(10):4999-5002.
[7] Haggstrom C,Stocks T,Rapp K,et al.Metabolic syndrome and risk of bladder cancer:prospective cohort study in the metabolic syndrome and cancer project(Me-Can)[J].Int J Cancer,2011,128(8):1890-1898.
[8] Haggstrom C,Rapp K,Stocks T,et al.Metabolic factors associated with risk of renal cell carcinoma[J].PLoS One,2013,8(2):e57475.
[9] 中华医学会糖尿病学分会代谢综合征研究协作组.中华医学会糖尿病学分会关于代谢综合征的建议[J].中华糖尿病杂志,2004,12(3):156-161.
[10] Godley P A,Stinchcombe T E.Renal cell carcinoma.[J].Curr Opin Oncol,1999,11(3):213-217.
[11] Esposito K,Chiodini P,Colao A,et al.Metabolic syndrome and risk of cancer:a systematic review and meta-analysis[J].Diabetes Care,2012,35(11):2402-2411.
[12] Ozbek E,Otunctemur A,Dursun M,et al.The metabolic syndrome is associated with more aggressive prostate cancer[J].Asian Pac J Cancer Prev,2014,15(9):4029-4032.
[13] Cicione A,De Nunzio C,Tubaro A,et al.Metabolic syndrome diagnosis and widespread high grade prostatic intraepithelial neoplasia significantly increase prostate cancer risk:results from a multicenter biopsy study[J].BMC Cancer,2015,16(1):59.
[14] Ozbek E,Otunctemur A,Dursun M,et al.Association between the metabolic syndrome and high tumor grade and stage of primary urothelial cell carcinoma of the bladder[J].Asian Pac J Cancer Prev,2014,15(3):1447-1451.
[15] Bulut S,Aktas B K,Erkmen A E,et al.Metabolic syndrome prevalence in renal cell cancer patients[J].Asian Pac J Cancer Prev,2014,15(18):7925-7928.
[16] Cardillo T M,Trisal P,Arrojo R,et al.Targeting both IGF-1R and mTOR synergistically inhibits growth of renal cell carcinoma in vitro[J].BMC Cancer,2013,13:170.
[17] Wulaningsih W,Garmo H,Holmberg L,et al.Serum Lipids and the Risk of Gastrointestinal Malignancies in the Swedish AMORIS Study[J].J Cancer Epidemiol,2012,2012:792034.
[18] Inoue M,Noda M,Kurahashi N,et al.Impact of metabolic factors on subsequent cancer risk:results from a large-scale population-based cohort study in Japan[J].Eur J Cancer Prev,2009,18(3):240-247.
[19] Magura L,Blanchard R,Hope B,et al.Hypercholesterolemia and prostate cancer:a hospital-based casecontrol study[J].Cancer Causes Control,2008,19(10):1259-1266.
[20] Magura L,Blanchard R,Hope B,et al.Hypercholesterolemia and prostate cancer:a hospital-based casecontrol study[J].Cancer Causes Control,2008,19(10):1259-1266.
[21] Pothiwala P,Jain S K,Yaturu S.Metabolic syndrome and cancer[J].Metab Syndr Relat Disord,2009,7(4):279-288.
[22] Kucharska-Newton A M,Rosamond W D,Mink P J,et al.HDL-cholesterol and incidence of breast cancer in the ARIC cohort study[J].Ann Epidemiol,2008,18(9):671-677.
[23] Lim U,Gayles T,Katki H A,et al.Serum high-density lipoprotein cholesterol and risk of non-hodgkin lymphoma[J].Cancer Res,2007,67(11):5569-5574.
[24] Horiguchi A,Ito K,Sumitomo M,et al.Decreased serum adiponectin levels in patients with metastatic renal cell carcinoma[J].Jpn J Clin Oncol,2008,38(2):106-111.
[25] Zhang G M,Zhu Y,Ye D W.Metabolic syndrome and renal cell carcinoma[J].World J Surg Oncol,2014,12(1):236.11
-
计量
- 文章访问数: 260
- PDF下载数: 224
- 施引文献: 0
下载: